VERTEX PHARMACEUTICALS INC / MA — Director's Dealing 2022

Mar 21, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK: 0000875320
Period of Report: 2022-03-17

Reporting Person: Sanna Bastiano (EVP, Cell & Genetic Therapies)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-03-17	Common Stock	S	2122	$250.06	Disposed	48412	Direct

Footnotes

F1: Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1.

F2: Open market sales reported on this line occurred at a weighted average price of $250.06 (range $250.00 to $250.48).

F3: Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.